<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620746</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00220384</org_study_id>
    <secondary_id>HHSN272201300012I/HHSN27200015</secondary_id>
    <nct_id>NCT04620746</nct_id>
  </id_info>
  <brief_title>Penicillin Allergy Testing in STD Clinics</brief_title>
  <official_title>Validate an Easy to Administer Algorithm to Define Penicillin (PCN-B-lactam) Allergy Status in Sexually Transmitted Disease (STD) Clinic Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstration project to implement penicillin allergy testing in STD outpatients using a&#xD;
      questionnaire and pen allergy testing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      all subjects receive risk questionnaire For subjects without high risk responses, randomized&#xD;
      to direct oral challenge or PCN skin testing followed by oral challenge&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity in predicting true allergy as assessed by a questionnaire</measure>
    <time_frame>Immediately after intervention</time_frame>
    <description>PCN allergy questionnaire developed in consultation with experts and will be scored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of direct oral challenge as assessed by a composite score to be designed</measure>
    <time_frame>Immediately after intervention</time_frame>
    <description>In subjects with low PCN allergy risk, direct oral challenge will be evaluated for safety using a composite score from a number of assessments to be designed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptability of PCN Testing/Oral Challenge as assessed by a questionnaire</measure>
    <time_frame>Immediately after intervention</time_frame>
    <description>Brief Questionnaire to subjects on acceptability of PCN allergy testing in the STD clinic setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in provider assessment of feasibility of PCN Testing/Oral Challenge as assessed by a questionnaire</measure>
    <time_frame>Baseline and at the end of study, up to 18 months</time_frame>
    <description>Provider assessment of feasibility of providing PCN testing in the STD clinic setting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Penicillin Allergy</condition>
  <arm_group>
    <arm_group_label>Skin Testing Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Direct Oral Challenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin Major Determinant (PrePen) Skin Testing</intervention_name>
    <description>Skin testing followed by oral challenge with amoxicillin 250 mg single dose</description>
    <arm_group_label>Skin Testing Arm</arm_group_label>
    <other_name>Penicillin G Minor Determinant Skin Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Direct Oral challenge</intervention_name>
    <description>Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose</description>
    <arm_group_label>Direct Oral Challenge</arm_group_label>
    <arm_group_label>Skin Testing Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior history of PCN allergy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No immunodeficiency or contraindication to skin testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan M Zenilman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan M Zenilman</last_name>
    <phone>4105509080</phone>
    <email>jzenilma@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lora Fortenberry, MD</last_name>
      <email>lfortenb@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Lillis, MD</last_name>
      <email>rlilli@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <phone>504-326-6501</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake County Health Department</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice McNeil, MD</last_name>
      <email>cmcneil@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington-Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Leclair</last_name>
      <email>achein@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be uploaded and provided when study is completed and analyzed. Estimated date is 3 months after study completion, mid 2022</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

